A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Secukinumab (Primary) ; Adalimumab
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms EXCEED 1
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 22 Aug 2017 Planned End Date changed from 1 Nov 2019 to 12 Nov 2020.
- 15 Jun 2017 Status changed from not yet recruiting to recruiting according to a Novartis media release.
- 15 Aug 2016 Planned number of patients changed from 852 to 850.